Shen-Shuai-Ning granule decreased serum concentrations of indoxyl sulphate in uremic patients undergoing peritoneal dialysis

作者：Chen, Xujiao; Gao, Shouhong; Ruan, Mengna; Chen, Sixiu; Xu, Jing; Xing, Xiaohong; Pan, Xiaohong; Mei, Changlin; Mao, Zhiguo^*

来源：Bioscience Reports, 2018, 38(5): BSR20171694.

DOI：10.1042/BSR20171694

• CHRONIC KIDNEY-DISEASE
• P-CRESYL SULFATE
• TRADITIONAL CHINESE MEDICINE
• ALL-CAUSE MORTALITY
• CARDIOVASCULAR-DISEASE
• INTESTINAL MICROBIOTA
• HEMODIALYSIS-PATIENTS
• THERAPEUTIC TARGETS
• GUT MICROBIOME
• RENAL-FUNCTION

Clearance of protein-bound uremic toxins (PBUTs) by dialysis is a challenge in the treatment of uremic patients. Shen-Shuai-Ning (SSN), a traditional Chinese medicine formulation, has been used commonly in China to retard kidney disease progression and decrease uremic toxins in chronic kidney disease (CKD) patients, but the effects of SSN on serum PBUTs in dialysis patients were not investigated. We conducted a randomized controlled trial in patients on peritoneal dialysis (PD) at dialysis center of Changzheng Hospital to evaluate the effects of SSN on serum PBUTs. Participants with SSN intervention took 5 g SSN granule three times daily for 12 weeks, while the baseline medications and dialysis prescriptions remained during the study in all patients. The serum concentrations of indoxyl sulphate (IS) and p-cresol sulphate (PCS) were determined by HPLC/MS/MS and biochemical parameters were assessed during the study. Sixty PD patients were enrolled and randomly allocated into SSN group and control group. Total IS level was significantly lower in SSN group than in control group at week 4, 8, and 12 (27.28 +/- 18.19, 29.73 +/- 19.10, and 29.41 +/- 17.61 mg/l compared with 39.25 +/- 20.23, 44.86 +/- 23.91, and 45.34 +/- 33.52 mg/l, respectively). However, there were no statistical difference of total PCS, free forms of IS and PCS concentrations between SSN group and control group during 12 weeks follow-up. Administration of SSN granule orally decreased serum total IS level effectively in uremic patients on PD with good tolerance. Benefits of PD patients' outcomes from IS reduction by SSN awaits further large size and long duration clinical trials to verify.

• 出版日期2018-10-31
• 单位中国人民解放军第二军医大学; 天津市中医药研究院附属医院